



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



# Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus

Vishvanath Tiwari

Department of Biochemistry, Central University of Rajasthan, Ajmer 305817, India

## ARTICLE INFO

### Article history:

Received 24 August 2020

Received in revised form 31 December 2020

Accepted 31 December 2020

Available online 7 January 2021

### Keywords:

Denovo designed antiviral

SARS-CoV2

RNA-dependent RNA polymerase (RdRp)

Retrosynthetic analysis

Molecular dynamics simulation

## ABSTRACT

A novel coronavirus disease (COVID-19) caused by SARS-CoV2 has now spread globally. Replication/transcription machinery of this virus consists of RNA-dependent RNA polymerase (nsp12 or RdRp) and its two cofactors nsp7 and nsp8 proteins. Hence, RdRp has emerged as a promising target to control COVID-19. In the present study, we are reporting a novel inhibitor VTRM1.1 against the RdRp protein of SARS CoV2. A series of antivirals were tested for binding to the catalytic residues of the active site of RdRp protein. In-silico screening, molecular mechanics, molecular dynamics simulation (MDS) analysis suggest ribavirin, and remdesivir have good interaction with the binding site of the RdRp protein as compared to other antiviral investigated. Hence, ribavirin and remdesivir were used for the denovo fragments based antiviral design. This design, along with docking and MDS analysis, identified a novel inhibitor VTRM1 that has better interaction with RdRp as compared to their parent molecules. Further, to produce a lead-like compound, retrosynthetic analysis, and combinatorial synthesis were performed, which produces 1000 analogs of VTRM1. These analogs were analysed by docking and MDS analysis that identified VTRM1.1 as a possible lead to inhibit RdRp protein. This lead has a good docking score, favourable binding energy and bind at catalytic residues of the active site of RdRp. The VTRM1.1 also interacts with RdRp in the presence of RNA primer and other cofactors. It was also seen that, VTRM1.1 do not have off-target in human. Therefore, the present study suggests a hybrid inhibitor VTRM1.1 for the RNA-dependent RNA polymerase of SARS CoV2 that may be useful to control infection caused by COVID-19.

© 2021 Elsevier B.V. All rights reserved.

## 1. Introduction

A novel coronavirus disease (Covid-19) caused by SARS-CoV2 [1] has now spread globally [2]. It has shifted its epicenter at different places across the globe and has now spread in more than 200 countries. On March 11, 2020, the world health organization (WHO) declared this outbreak a pandemic. On Apr 15, 2020 there were > 15,00,00 cumulative cases globally and > 90,000 death with ~5% mortality rate in outcome cases. The main symptom of this disease includes fever, shortness of breath, cough, and gastrostomy complications. Coronavirus employs a multi-subunit replication/transcription machinery. Different non-structural proteins (nsp) produced as a cleavage product of ORF1a and ORF1b viral polyproteins [3] that are assemble to facilitate viral replication and transcription. A key component of this machinery is nsp12 also known as RNA-dependent RNA polymerase (RdRp), and responsible for RNA synthesis. RNA synthesis of nsp12 in SARS CoV is activated by two other non-structural proteins nsp7 and nsp8 [4]. In addition to that, this complex (nsp12/nsp7/nsp8) associates with nsp14 and

has shown 3'-5' exonuclease (involved in replication fidelity) and RNA cap N-7-guanine methyltransferase activities (associated with 5'-RNA capping) in SARS-CoV [4]. This shows the importance of RdRp in the biology of SARS-CoV2. Hence, to control COVID-19 infection, there is an urgent need to find an inhibitor for RdRp. It is also reported that nsp12 (or RdRp) was considered as a primary target to control the infection of SARS-CoV by different inhibitors [5]. RdRp can be a potential therapeutic target to control the infection caused by SARS CoV2 as its human homolog of this nsp12 has not reported [6] therefore, therapeutic against nsp12 may be significant to control the COVID-19. The attempt has made to evaluate the FDA approved molecule like Ribavirin, Remdesivir, etc. as an inhibitor of RdRp [7]. Remdesivir, Ritonavir, and Lopinavir have been used to control other coronaviruses [8]. Remdesivir (GS-5734) is a broad-spectrum antiviral nucleotide prodrug with potent antiviral activity against diverse RNA viruses like SARS-CoV, MERS-CoV [9]. Designing of a new molecule takes a long time to develop it as effective antiviral, hence in the present study, we have designed a denovo synthesized VTRM1.1 from FDA approved antiviral molecules against SARS-CoV2 RNA-dependent RNA polymerase using *in-silico* drug design, molecular mechanics, retrosynthetic analysis, combinatorial synthesis, and molecular dynamics simulation analysis.

E-mail address: [vishvanath@curaj.ac.in](mailto:vishvanath@curaj.ac.in).

## 2. Results

### 2.1. Receptor grid of RNA-dependent RNA polymerase (RdRp) was prepared targeted to the catalytic residue of the active site


The PDB structure of RNA-dependent RNA polymerase (RdRp) was taken from RCSB (PDB number 6m71, resolution 2.9 Å). This PDB structure has four chains [10] including nsp12 (chain A), nsp7 (chain C), nsp8 (chain B and chain D). The nsp12 consists of the thumb, palm, and finger domain (Fig. 1). The PDB structure showed that the active site of RdRp domain involves residues like Asp618 of the motif A; Ser759, Asp760, and Asp761 of motif C. It was also seen that Asp618, Asp760 and Asp761 are involved in the binding with  $Mn^{2+}$ ; Arg555, Val557, Asp623, Thr680, Ser682, Asn691, and Asp760 are involved in binding of UDP and Remdesivir [10]. Hence, these residues Asp618, Ser759, Asp760, Asp761, Asp623, Arg555, Val557, Ser682, Asn691, Thr680 were used for receptor grid generation. This receptor grid was used to screen antiviral molecule targeting RdRp.

### 2.2. Selection of antiviral molecules

The antiviral molecules were selected based on the currently available literature search and their efficacy on the SARS-CoV2. The selected antiviral drugs in the present study were remdesivir, ribavirin, favipiravir, ritonavir, umifenovir, hydroxychloroquine, ascorbate, oseltamivir, tenofovir, and acetyl-serine. The ligand preparation of these antiviral molecules has resulted in the 87 tautomers, and prepared ligands were investigated for its interaction with the binding site of RdRp.

### 2.3. Virtual screening showed that ribavirin, and remdesivir have best docking in the active site of RdRp protein

We have performed docking studied in HTVS, SP, and XP mode. Docking results suggested that among all the antiviral molecules investigated, ribavirin (G-score,  $-6.109$  kcal/mol) and remdesivir (G-score,  $-6.038$  kcal/mol) have shown better interaction with the active site of RdRp (Supplementary Table ST1). The docking poses are shown in



**Fig. 1.** Binding sites of SARS-CoV2 RNA-dependent RNA polymerase (nsp12) complexed with cofactors nsp7 and nsp8. The figure shows the thumb, palm, and fingers domain of the nsp12 protein.

Fig. 2, and docking scores, along with binding energies, are shown in Table 1. The residues of RdRp protein that interact with individual antiviral molecules are different for both antiviral molecules. Ribavirin involves Arg553, Arg555, Thr556, Ser682, Arg624, Asp623, Cys622, Lys621, Pro620, Tyr619 and Asp760 (Fig. 2A) while remdesivir interacts with Trp617, Ap618, Tyr619, Lys621, Cys622, Asp623, Ard624, Asp760, Asp761, Lys545, Lys551, Arg553, Arg555, Thr556, Val557, Ser682, Tyr455, Glu811, and Ser814 (Fig. 2C). It is also seen in the present study that the interaction of both the antiviral involves the crucial amino acid of RdRp that are involved in the catalysis of this enzyme.

### 2.4. Remdesivir and ribavirin have favourable binding free energy with RdRp

All the antivirals were undergone molecular mechanics analysis with generalized born and surface area solvation (MM-GBSA) methods to calculate the Gibbs free energy of binding. The result of this analysis is listed in Table 1. It was found that all the molecules investigated, have favourable Gibbs free energy change for binding to RdRp. Antivirals were first filtered by docking scores, followed by Gibbs free energy if their docking scores were similar. Based on docking and binding free energy results, remdesivir and ribavirin are selected for the further study. As these two molecules are nucleotide analog, hence the interaction of different NTP and dNTPs with the RdRp was also monitored. The result showed that Remdesivir has better binding energy as compared to native nucleotides (ATP, GTP, CTP, UTP), while ribavirin has better binding energy than NTPs like ATP (Supplementary Table ST2).


### 2.5. Denovo fragment-based designing and MDS analysis identified VTRM1 as possible lead targeting the active site of RdRp

Denovo fragment-based drug designing was started with the fragmentation of the selected molecules, i.e., ribavirin, and remdesivir. A total of 93 fragments were produced that includes 5 fragments of ribavirin, and 88 fragments of remdesivir. All the 93 fragments were docked (in SP mode) to the grid of binding site of RdRp protein. Based on manual analysis of docked complexes, different fragments (fragment 4 and 5 of ribavirin; fragment 60, 61, 62, 63, 68, 71, 73, 75, 76, 86, and 87 of remdesivir) were selected for denovo fragment-based design using Breed. The breed produces 14 combinations. These 14 combinations, along with two-parent molecules (remdesivir and ribavirin), were docked (in XP mode) to the binding site of RdRp protein. That selects the denovo hybrid Breed of fragment 60 and 73 of remdesivir, which has the best docking (G-score,  $-7.953$  kcal/mol). This docking score was found to be higher than their parent molecules (Table 1) and named as 'VTRM1', and chemically (2R,3R,4S,5R)-2-{4-aminopyrrolo [2,1-f][1,2,4]triazin-7-yl}-5-({(S)-({3-[(2R,3S,4R,5S)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxyoxolan-2-yl]-2-oxopropyl)amino)(phenoxy)phosphoryl}oxy)methyl)-3,4-dihydroxyoxolane-2-carbonitrile (Fig. 2E and F). To further confirm the interaction, the MDS analysis of the VTRM1-RdRp protein complex was performed. The result showed that RMSD of RdRp protein (in ligand complex state) was found to be  $<2$  Å, and ligand's RMSD is less than  $<4.8$  Å, that showed stable complex (Fig. 3A). RMSF analysis showed that most of the protein (except some part) has the RMSF  $<2$  Å that showed stable protein conformation (Fig. 3B). Further, the interaction between VTRM1 and RdRp protein was investigated and found that it involves Asp452, Arg553, Thr556, Asp618, Tyr619, Lys621, Cys622, Asp623, Arg624, Asp760, Asp761, Lys798, Glu811, and at least nine contacts always exist more than 30% simulation time (Fig. 3D).

### 2.6. Retrosynthetic analysis, combinatorial synthesis, and MDS analysis identified VTRM1.1 as an antiviral targeted to the binding site of RdRp protein

To produce lead-like compounds, retrosynthetic analysis, and combinatorial synthesis was performed that produced 1000 analogs of





**Fig. 2.** Interaction diagram showing interacting amino acid residues and their docking pose in SARS-CoV2 RdRp. RdRp-Ribavirin complex (A and B), RdRp-Remdesivir complex (C and D), and RdRp-VTRM1 complex (E and F).

VTRM1 by more than 100 modifications. The 1000 products were prepared and docked to the active site of RdRp protein. Docking and binding energy calculation identified VTRM1.1 as best docked molecule (G-score,  $-7.239$  kcal/mol) among different modified products, and identified as (1R)-1-(4-(((4aR,8aR)-4a-hydroxy-decahydroisquinolin-2-yl)methyl)-2-aminophenyl)-2-aminoethyl-N-[3-cyclopropylimidazo[1,5-a]pyridin-1-yl]carbamate (Fig. 4A and B). The second molecule has been named VTRM1.2 and chemically; it is (2R)-1-amino-4-(1H-1,3-benzodiazol-2-ylsulfanyl)butan-2-ol (Fig. 4C and D).

To further confirm the interaction, the MDS analysis of the VTRM1.1-RdRp (Fig. 5) and VTRM1.2-RdRp complex (Supplementary figure SF1) was performed. The MDS result of VTRM1.1-RdRp complex showed that RMSD of protein (in ligand complex state) is  $<2$  Å and ligand (in protein complex state) have RMSD  $<4$  Å that showed a very stable complex (Fig. 5A). RMSF analysis showed that most of the protein has the RMSF  $<2.5$  Å that showed stable protein conformation (Fig. 5B). Interaction between VTRM1.1 and RdRp protein involves at least nine contacts that always exist more than 30% simulation time (Fig. 6A) and involves Arg553, Asp618, Lys621, Asp623, Arg624, Asp760, Asp761, Trp800, Glu811 amino acid residues (Fig. 6B). The ligand has a small deviation (RMSD  $<2.5$  Å)

**Table 1**

Result showing outcome of GLIDE molecular docking in XP mode and Binding free energies result from Prime analysis using MMGBSA approach. The docking was performed using Grid of core residues of active site of RNA-dependent RNA polymerase.

Antiviral molecules	Docking score (in Kcal/mol)	Glide E-model (in kcal/mol)	Binding gibbs free energy change (in kcal/mol)
Ribavirin	-6.11	-39.97	-24.87
Remdesivir	-6.04	-72.07	-41.04
VTRM1	-7.95	-99.57	-34.44
VTRM1.1	-7.24	-79.89	-53.39
VTRM1.2	-5.28	-48.47	-36.63
GTP	-6.42	-116.24	-36.12
ATP	-6.12	-98.25	-19.99

during the simulation with reference to its conformation at the start of the simulation (Fig. 6C). Ligand has only one intramolecular hydrogen bonding till 18 ns after that there is no intramolecular bonding, which further suggests stable conformation of ligands. The van der Waals surface area (MolSA), solvent accessible surface area (SASA), polar surface area (PSA) also supported the good interaction between ligand and RdRp (Fig. 6C).


In Fig. 7A, the top panel shows the total number of specific contacts of protein with ligand throughout the trajectory. The bottom panel shows interacting residues of protein with ligand in each trajectory frame (Fig. 7A). This confirms a good interaction of VTRM1.1 with catalytically active amino acid residues like Asp760, Asp761, Asp623 of RdRp. In Fig. 7B, the secondary structure element (SSE) composition for each trajectory frame throughout the simulation are shown, and the plot at the bottom monitors each residue and its SSE assignment over time (Fig. 7). The result confirms that the SSE remains very similar throughout the simulation that confirm the stable interaction.

### 2.7. VTRM1.1 has better ADMET properties than VTRM1

In addition to this, ADMET analysis of all the selected lead molecules, i.e., VTRM1, VTRM1.1, and VTRM1.2 were performed, and their results are shown in Table 2. The comparative analysis showed that although VTRM1 has the best docking score but it has bad ADMET properties that make it a weak lead. The VTRM1.1 has better ADMET parameters and has the docking and binding energy very close to VTRM1; hence VTRM1.1 is suggested as a possible inhibitor for RdRp of SARS CoV2.

### 2.8. VTRM1.1 interacts with RdRp protein in the presence of RNA primer and other cofactors

To further validate the biological relevance of the designed lead, the interaction of the VTRM1.1 with RdRp was monitored in the presence of RNA primer and other cofactors. The result showed that the binding of



**Fig. 3.** Root-mean-square deviation (A) and Root mean square fluctuations (B), Interacting residues (C), and the interacting fraction (D) during molecular dynamics simulation analysis of RdRp-VTRM1 complex.

VTRM1.1 with RdRp is favourable ( $-51.67$  kcal/mol) in the presence of RNA and other metal cofactors (Supplementary Table ST3) that further supports the biological significance of the lead molecule.

### 2.9. VTRM1.1 has no human off-targets

Presence of lead's off-targets in human may reduce the efficacy and produce the side effect. Hence, human off-targets of VTRM1.1 was predicted using Swiss Target Prediction. The result showed that the designed lead VTRM1.1 do not possess any off-targets in human. This further enhances the significance of VTRM1.1 as a possible lead against the RdRp.

## 3. Discussion


SARS-CoV2 has emerged as a lethal pathogen causing a global pandemic. No specific FDA approved treatment is available for COVID-19. Some non-specific treatments like remdesivir, ribavirin, etc. [11] are used. Ribavirin is a guanosine analog that has been reported to have multiple mechanisms of action [12] and has also shown to have an inhibitory effect against SARS-CoV2 [13]. Remdesivir (GS-5734) is currently used with lopinavir against COVID-19 without knowing its specific targets in SARS-CoV2 [14]. The essential components of the replication/transcription machinery of SARS CoV2 are RNA-dependent RNA polymerase (nsp12 or RdRp) along with its two cofactors nsp7 and nsp8. In addition to this, this complex nsp12/nsp7/nsp8 binds with nsp14, which then modulates replication fidelity and 5'-RNA capping in SARS-CoV [4]. Human homologs of nsp12 have not reported [6], hence, RdRp can be a potential therapeutic target to control the infection

caused by SARS CoV2. In the present study, a novel inhibitor VTRM1.1 targeting to RdRp was designed using denovo designing, retrosynthetic analysis, and combinatorial synthesis, and molecular dynamic simulation.

PDB structure of RdRp was retrieved from the RCSB, and the grid was prepared at an active site that binds with metal and nucleoside-diphosphate (NDP). The docking, binding energy calculation, and molecular dynamic simulation calculation have shown that ribavirin and remdesivir have good interactions with the active site of RdRp. Various in-vitro experimental data suggest that the ribavirin has shown an inhibitory effect on SARS-CoV2 [13]. Similarly, remdesivir effectivity inhibits the 2019-nCoV in-vitro [15] by delayed chain termination and inhibits RNA synthesis [16]. Recently, it is also seen that it incorporate into the primer stand at the first replicated base pair and terminates chain elongation [17]. An in-silico study on the modeled RdRp has also shown that the ribavirin and remdesivir has the best interaction with RdRp among the approved antiviral investigated [18].

To find a novel inhibitor, we have used denovo fragment-based drug design using FDA approved antiviral molecules ribavirin and remdesivir that showed direct interaction with the active site of RdRp of SARS CoV2. A total of 93 fragments were generated from these two molecules. They were docked to the binding site of RdRp, and best-docked fragments were manually analysed of its interaction with RdRp. The selected fragments were joined via denovo fragment-based drug design. This approach joined the different fragments based on the structural similarity to the active molecules and their scaffolds, hence used to navigate a considerable chemical space [19]. The hybrid antiviral was further confirmed for its interaction with the active site of RdRp using the XP-mode of docking and molecular dynamics simulations. This






**Fig. 4.** Interaction diagram showing interacting amino acid residues and their docking pose in SARS-CoV2 RdRp with denovo synthesized antiviral showing RdRp-VTRM1.1 complex (A and B), RdRp-VTRM1.2 complex (C and D).


select VTRM-1 as a possible denovo synthesized hybrid molecule that can interact with RdRp and involves Asp618, Asp760, Asp761 amino acid residue that is important for the catalysis of this protein [10]. VTRM1 has many ADMET parameters outside its permissible limit; hence, it was modified.

Optimization of lead required the synthesis and validation of thousands of lead's analogs before clinical candidate nomination, which takes a longer time. Further, to explore possible improvement in the

VTRM1, we have used *in-silico* based retrosynthetic analysis, combinatorial synthesis, and MDS analysis to design an improved new antiviral molecule. Retrosynthetic analysis followed by combinatorial synthesis generates 1000 analogs of the denovo designed hybrid molecules (VTRM1) and analysed for its interaction with the active site of RdRp. ADMET properties is very important for the selection of drug candidates. VTRM1.1 has shown docking, and binding free energy value close to VTRM1, but its ADMET properties are better than VTRM1;




**Fig. 5.** Root-mean-square deviation (A) and Root mean square fluctuations (B), during molecular dynamics simulation analysis of RdRp-VTRM1.1 complex.



**Fig. 6.** Interacting fraction (A), interacting residues (B), properties of ligand (C), during molecular dynamics simulation analysis of RdRp-VTRM1.1 complex.

hence VTRM1.1 is identified as better lead than VTRM1. MDS analysis confirms the interaction of VTRM1.1 with the active site of RdRp. It involves the catalytically critical residue (Asp760 and Asp761) of the active site of this protein that is important for the binding metal ion and

catalysis. This showed that modification by retro-combinatorial synthesis does not alter the docking and binding energy of the denovo synthesized molecule VTRM1.1 but improves ADMET properties that enhance the drug-likeness nature of the designed units. The in-vivo condition



**Fig. 7.** Representation of the interactions and contacts (H-bonds, Hydrophobic, Ionic, Water bridges) between VTRM1.1 with RdRp protein (A), and protein secondary structure elements (SSE) during simulation of RdRp-VTRM1.1 complex (B).

**Table 2**

Result showing outcome of ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) analysis. The prediction was performed using QikProp analysis.

ADMAT properties (normal range)	VTRM1	VTRM1.1	VTRM1.2
mol MW (130 to 725)	736.636	518.658	237.319
donorHB (1 to 6)	9	5.5	4
accptHB (2 to 20)	24.75	8.75	4.2
QPpolarz (13–70)	63.451	53.612	63.451
QPlogPC16 (4 to 18)	23.978	17.059	8.978
QPlogPoct (8 to 35)	50.513	31.124	15.621
QPlogPw (4 to 45)	41.519	19.223	11.593
QPlogPo/w (−2 to 6.5)	−1.965	2.812	1.008
QPlogS (−6.5 to 0.5)	−3.941	−3.492	−1.817
QPlogBB (−3 to 1.2)	−5.156	−1.006	−0.596
QPlogKp (−8 to −1)	−6.038	−7.192	−4.7
QPlogKhsa	−1.524	0.557	−0.486
Human Oral Absorption (2 to 3)	1	2	3
Percent Human Oral Absorption	0	37.366	70.8
Rule Of Five	3	2	0
Rule Of Three	2	2	0
QPlogHERG	−7.305	−7.303	−5.61
QPPCaco	1.189	12.888	131.943

involves the presence of RNA in the active site of RdRp hence we have further validated hybrid leads for its interaction with RdRp in the presence of RNA and metal cofactors. The result confirms the interaction between VTRM1.1 and RdRp in the presence of an RNA molecule. Hence, the present study reports *denovo* designing, retrosynthetic analysis, and combinatorial synthesis, molecular dynamic simulation based design of a novel antiviral VTRM1.1 that may be a possible inhibitor of RNA dependent RNA polymerase of SARS CoV2. This molecule VTRM1.1 need to be synthesized and experimentally tested against SARS-CoV, in animal and humans before been use as therapeutics.

## 4. Methods

### 4.1. Retrieval of the structure of RNA-dependent RNA polymerase

The PDB structure of SARS-CoV2 RNA-dependent RNA polymerase (RdRp) is available hence retrieved from RCSB (PDB number 6M71, resolution 2.9 Å). The structure was pre-processed by assign bond orders, add hydrogens, create zero-order bonds for metals, create disulfide bonds, optimise for water orientation and pH, and reduce for converge heavy atoms to 0.3RMSD using OPLS\_2005 force field. The residues Asp618, Ser759, Asp760, Asp761, Asp623, Arg555, Val557, Ser682, Asn691, Thr680 are used for receptor grid generation. This receptor grid was used to screen several antiviral molecules.

### 4.2. Ligand preparation

The antiviral currently prescribed for COVID-19 [8,14,11,5] were selected in the present study. The selected antiviral drugs were remdesivir, ribavirin, favipiravir, ritonavir, umifenovir, hydroxychloroquine, ascorbate, oseltamivir, tenofovir, acetyl-serine. The SDF structure of the antiviral molecules was downloaded from the PubChem database. These SDF structures, along with *denovo* design hybrid antiviral leads, were prepared by using LigPrep modules of the Schrodinger as per our published protocol [20].

### 4.3. Virtual screening of antiviral on the RNA-dependent RNA polymerase

All the prepared ligands were used for virtual testing of antiviral that docked to the grid of RNA-dependent RNA polymerase as per our published protocol [21]. The docking score predicts the binding affinity between the target protein and particular pose of ligand docked. *E*-model is used to compare conformers of same ligand based on electrostatic and van der Waals energies. The virtual screening was performed in three

modes of docking i.e., HTVS, SP, and XP mode [22]. HTVS and SP docking use a series of hierarchical filters to search for possible locations of the ligand in the binding site of the receptor. HTVS and SP use the same scoring function, but HTVS reduces the number of intermediate conformations in docking and also reduces the thoroughness of final torsional refinement and sampling. In contrast, Extra Precision (XP) mode employs an anchor and grow sampling approach for the docking.

### 4.4. Molecular mechanics/generalized born surface area (MM-GBSA) calculations of selected library compounds

Binding free energy is the sum of total intermolecular interactions that is present between ligand and protein. To get more accurate interaction, XP docked antiviral molecules with RNA-dependent RNA polymerase were further subjected to molecular mechanics with generalized born surface area (MM-GBSA) calculations using the Prime module of Schrodinger as per our published methods [23].

### 4.5. Molecular dynamics simulation (MDS) analysis

MDS was performed using Desmond modules of the Schrodinger 2019–4 as per published methods [24] using the OPLS3e force field. The system was built for the protein-ligand complex using the TIP3P solvent model; sodium ion was added to make charge-neutral, 0.15 M NaCl was added to make the system close to the natural system. The simulation was run for 5 ns (or 25 ns for VTRM1.1-RdRp complex), with 5 ps trajectory recording intervals. System energy was set to be 1.2, and the ensemble class used was NPT. The simulation was set to run at 300 k at 1.01325 bar. The option to relax the system before simulation was selected. The simulated system was analysed for the simulation interaction diagram.

### 4.6. *Denovo* fragment-based drug design

*De-novo* fragment-based drug designing is a newly emerged approach [19]. The different fragments of selected antiviral molecules were generated. The various fragments of ligands were docked into the binding site of the RdRp. The docked complex was manually analysed for its position of docking in the binding site. Different fragments (fragments 4 and 5 of ribavirin; fragment 60, 61, 62, 63, 68, 71, 73, 75, 76, 86, and 87 of remdesivir) were selected based on their interaction to the binding site of the RdRp. The selected fragments were joined using the Breed module to generate newly *denovo* designed antiviral molecules. The *denovo* designed antiviral molecules were further confirmed for its interaction with the binding site of the RdRp using XP-docking and molecular dynamics simulations analysis.

### 4.7. Retrosynthetic analysis and combinatorial synthesis

To produce synthetically tractable lead-like compounds, retrosynthetic analysis, and combinatorial synthesis were performed for the *denovo* synthesized VTRM.1 as per the published method using PathFinder [25]. PathFinder can incorporate more than 100 reactions like C—C bond formation that are required for the molecular scaffolds and drug discovery [26]. A total of 100 number of pathways are investigated to produce 1000 products. The top 10% product that is similar to the input molecule VTRM.1 are selected for further analysis. The selected 1000 products were analysed by docking, and molecular dynamics simulations analysis to select the antiviral lead.

### 4.8. ADMET analysis of the selected lead

The ADMET analysis was performed that identified absorption distribution, metabolism, excretion, and toxicity of the leads molecule using QikProp as per published protocol [27].



#### 4.9. Validation of lead for its interaction with the RdRp-RNA complex

The interaction of lead with RdRp in the presence of cofactors has a biological relevance, hence the PDB structure of RdRp complexed with primer RNA, cofactors, and remdesivir was retrieved from RCSB (PDB number 7BV2, resolution 2.5 Å). The remdesivir was removed from the complex, and the structure was pre-processed, optimised, minimised to 0.3RMSD using the OPLS\_2005 force field. The residues Asp618, Ser759, Asp760, Asp761, Asp623, Arg555, Val557, Ser682, Asn691, Thr680 are used for receptor grid generation. This receptor grid was used to validate the selected leads.

#### 4.10. Identification of human off-targets of designed lead VTRM1.1

The human off-targets of the designed lead was predicted using Swiss Target Prediction [28] using the published protocol [29].

#### Author Contributions

Conceived and designed the experiments: V.T., Performed the experiments: V.T., Analysed the data: V.T., Wrote the manuscript: V.T., Proof-read of the final version: V.T.

#### Declaration of competing interest

The author have declared that no competing interests exist. The experiment was performed in the absence of any financial support.

#### Acknowledgments

I would like to thank the Central University of Rajasthan for providing the Schrodinger suite. I would like to thank Monalisa Tiwari for proofreading the manuscript.

#### Ethical approval

The present study does not involve human and animal samples.

#### Data availability

All the data are available in the manuscript.

#### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jbiomac.2020.12.223>.

#### References

- [1] A.E. Gorbalenya, S.C. Baker, R.S. Baric, R.J. de Groot, C. Drosten, A.A. Gulyaeva, B.L. Haagmans, C. Lauber, A.M. Leontovich, B.W. Neuman, D. Penzar, S. Perlman, L.L. Poon, D. Samborskiy, I.A. Sidorov, I. Sola, J. Ziebuhr, The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, *Nat. Microbiol.* 5 (4) (2020) 536–544.
- [2] F. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, Y.L. Zhang, F.H. Dai, Y. Liu, Q.M. Wang, J.J. Zheng, L. Xu, E.C. Holmes, Y.Z. Zhang, A new coronavirus associated with human respiratory disease in China, *Nature* 579 (7798) (2020) 265–269.
- [3] J. Ziebuhr, The coronavirus replicase, *Curr. Top. Microbiol. Immunol.* 287 (2005) 57–94.
- [4] L. Subissi, C.C. Posthuma, A. Collet, J.C. Zevenhoven-Dobbe, A.E. Gorbalenya, E. Decroly, E.J. Snijder, B. Canard, I. Imbert, One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities, *Proc. Natl. Acad. Sci.* 111 (37) (2014), E3900.
- [5] M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, *Cell Res.* 30 (3) (2020) 269–271.
- [6] C. Wu, Y. Liu, Y. Yang, P. Zhang, W. Zhong, Y. Wang, Q. Wang, Y. Xu, M. Li, X. Li, M. Zheng, L. Chen, H. Li, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, *Acta Pharm. Sin. B* 10 (5) (2020) 766–788.
- [7] A.A. Elfiky, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study, *Life Sci.* 253 (2020) 117592.
- [8] T.P. Sheahan, A.C. Sims, S.R. Leist, A. Schafer, J. Won, A.J. Brown, S.A. Montgomery, A. Hogg, D. Babusis, M.O. Clarke, J.E. Spahn, L. Bauer, S. Sellers, D. Porter, J.Y. Feng, T. Cihlar, R. Jordan, M.R. Denison, R.S. Baric, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, *Nat. Commun.* 11 (1) (2020) 222.
- [9] T.P. Sheahan, A.C. Sims, R.L. Graham, V.D. Menachery, L.E. Gralinski, J.B. Case, S.R. Leist, K. Pyrc, J.Y. Feng, I. Trantcheva, R. Bannister, Y. Park, D. Babusis, M.O. Clarke, R.L. Mackman, J.E. Spahn, C.A. Palmiotti, D. Siegel, A.S. Ray, T. Cihlar, R. Jordan, M.R. Denison, R.S. Baric, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, *Sci. Transl. Med.* 9 (396) (2017).
- [10] Y. Gao, L. Yan, Y. Huang, F. Liu, Y. Zhao, L. Cao, T. Wang, Q. Sun, Z. Ming, L. Zhang, J. Ge, L. Zheng, Y. Zhang, H. Wang, Y. Zhu, C. Zhu, T. Hu, T. Hua, B. Zhang, X. Yang, J. Li, H. Yang, Z. Liu, W. Xu, L.W. Guddat, Q. Wang, Z. Lou, Z. Rao, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, *Science* 368 (6492) (2020) 779–782.
- [11] A.K. Singh, A. Singh, A. Shaikh, R. Singh, A. Misra, Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries, *Diabetes Metab Syndr* 14 (3) (2020) 241–246.
- [12] V. Loustaud-Ratti, M. Debette-Gratien, J. Jacques, S. Alain, P. Marquet, D. Sautereau, A. Rousseau, P. Carrier, Ribavirin: past, present and future, *World J. Hepatol.* 8 (2) (2016) 123–130.
- [13] J.S. Khalili, H. Zhu, N.S.A. Mak, Y. Yan, Y. Zhu, Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19, *J. Med. Virol.* 92 (7) (2020) 740–746.
- [14] K.T. Choy, A. Yin-Lam Wong, P. Kaewpreedee, S.F. Sia, D. Chen, K.P. Yan Hui, D.K. Wing Chu, M.C. Wai Chan, P. Pak-Hang Cheung, X. Huang, M. Peiris, H.L. Yen, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, *Antivir. Res.* 104786 (2020).
- [15] M. Wang, R. Cao, L. Zhang, X. Yang, J. Liu, M. Xu, Z. Shi, Z. Hu, W. Zhong, G. Xiao, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, *Cell Res.* 30 (3) (2020) 269–271.
- [16] C.J. Gordon, E.P. Tchesnokov, E. Woolner, J.K. Perry, J.Y. Feng, D.P. Porter, M. Götte, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, *J. Biol. Chem.* 295 (2020) 6785–6797.
- [17] W. Yin, C. Mao, X. Luan, D.-D. Shen, Q. Shen, H. Su, X. Wang, F. Zhou, W. Zhao, M. Gao, S. Chang, Y.-C. Xie, G. Tian, H.-W. Jiang, S.-C. Tao, J. Shen, Y. Jiang, H. Jiang, Y. Xu, S. Zhang, Y. Zhang, H.E. Xu, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, *Science (New York, N.Y.)* 368(6498) (2020) 1499–1504.
- [18] A.A. Elfiky, Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study, *Life Sci.* 253 (2020) 117592.
- [19] K. Kawai, N. Nagata, Y. Takahashi, De novo design of drug-like molecules by a fragment-based molecular evolutionary approach, *J. Chem. Inf. Model.* 54 (1) (2014) 49–56.
- [20] V. Tiwari, V. Patel, M. Tiwari, In-silico screening and experimental validation reveal L-adrenaline as anti-biofilm molecule against biofilm-associated protein (Bap) producing *Acinetobacter baumannii*, *Int J Biol Macromol* 107(Pt A) (2018) 1242–1252.
- [21] P. Verma, V. Tiwari, Targeting outer membrane protein component AdeC for the discovery of efflux pump inhibitor against AdeABC efflux pump of multidrug resistant *Acinetobacter baumannii*, *Cell Biochem. Biophys.* 76 (3) (2018) 391–400.
- [22] R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis, P.S. Shenkin, Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy, *Journal of Medicinal Chemistry* 47(7) (2004) 1739–1749.
- [23] V. Tiwari, M.R. Rajeswari, M. Tiwari, Proteomic analysis of iron-regulated membrane proteins identify FhuE receptor as a target to inhibit siderophore-mediated iron acquisition in *Acinetobacter baumannii*, *Int. J. Biol. Macromol.* 125 (2019) 1156–1167.
- [24] W.C. Wright, J. Cheng, J. Wang, H.M. Girvan, L. Yang, S.C. Chai, A.D. Huber, J. Wu, P.O. Oladimeji, A.W. Munro, T. Chen, Clobetasol propionate is a heme-mediated selective inhibitor of human cytochrome P450 3A5, *J. Med. Chem.* 63 (3) (2020) 1415–1433.
- [25] K.D. Konze, P.H. Bos, M.K. Dahlgren, K. Leswing, I. Tubert-Brohman, A. Bortolato, B. Robbason, R. Abel, S. Bhat, Reaction-based enumeration, active learning, and free energy calculations to rapidly explore synthetically tractable chemical space and optimize potency of cyclin-dependent kinase 2 inhibitors, *J. Chem. Inf. Model.* 59 (9) (2019) 3782–3793.
- [26] G.W. Bemis, M.A. Murcko, The properties of known drugs. 1. Molecular frameworks, *J Med Chem* 39(15) (1996) 2887–93.
- [27] M. Tiwari, S. Panwar, A. Kothidar, V. Tiwari, Rational targeting of Wzb phosphatase and Wzc kinase interaction inhibits extracellular polysaccharides synthesis and biofilm formation in *Acinetobacter baumannii*, *Carbohydr. Res.* 492 (2020) 108025.
- [28] A. Daina, O. Michielin, V. Zoete, SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules, *Nucleic Acids Res.* 47 (W1) (2019) W357–W364.
- [29] V. Tiwari, K. Meena, M. Tiwari, Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup, *Infect. Genet. Evol.* 66 (2018) 57–65.